Khiewvan Benjapa, Torigian Drew A, Emamzadehfard Sahra, Paydary Koosha, Salavati Ali, Houshmand Sina, Werner Thomas J, Alavi Abass
Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA.
Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, 10700.
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1079-1091. doi: 10.1007/s00259-017-3638-z. Epub 2017 Feb 8.
This review article summarizes the role of PET/CT and PET/MRI in ovarian cancer. With regard to the diagnosis of ovarian cancer, the presence of FDG uptake within the ovary of a postmenopausal woman raises the concern for ovarian cancer. Multiple studies show that FDG PET/CT can detect lymph node and distant metastasis in ovarian cancer with high accuracy and may, therefore, alter the management to obtain better clinical outcomes. Although PET/CT staging is superior for N and M staging of ovarian cancer, its role is limited for T staging. Additionally, FDG PET/CT is of great benefit in evaluating treatment response and has prognostic value in patients with ovarian cancer. FDG PET/CT also has value to detect recurrent disease, particularly in patients with elevated serum CA-125 levels and negative or inconclusive conventional imaging test results. PET/MRI may beneficial for tumor staging because MRI has higher soft tissue contrast and no ionizing radiation exposure compared to CT. Some non-FDG PET radiotracers such as F-fluorothymidine (FLT) or C-methionine (MET) have been studied in preclinical and clinical studies as well and may play a role in the evaluation of patients with ovarian cancer.
这篇综述文章总结了PET/CT和PET/MRI在卵巢癌中的作用。关于卵巢癌的诊断，绝经后女性卵巢内出现氟代脱氧葡萄糖（FDG）摄取会引发对卵巢癌的担忧。多项研究表明，FDG PET/CT能够高精度检测卵巢癌的淋巴结转移和远处转移，因此可能会改变治疗方案以获得更好的临床结果。尽管PET/CT分期在卵巢癌的N和M分期方面更具优势，但其在T分期中的作用有限。此外，FDG PET/CT在评估治疗反应方面具有很大益处，并且对卵巢癌患者具有预后价值。FDG PET/CT在检测复发性疾病方面也具有价值，特别是对于血清CA - 125水平升高且传统影像学检查结果为阴性或不确定的患者。PET/MRI可能对肿瘤分期有益，因为与CT相比，MRI具有更高的软组织对比度且无电离辐射暴露。一些非FDG PET放射性示踪剂，如F - 氟胸苷（FLT）或C - 蛋氨酸（MET），也已在临床前和临床研究中进行了研究，并且可能在卵巢癌患者的评估中发挥作用。
